Skip to content
10-Q

Quarterly Report

VERTEX PHARMACEUTICALS INC / MA VRTX

0000875320-26-000173

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 253.81M sh
Shares Diluted Q1 2026 · Mar 31, 2026 256.3M sh
Shares Diluted Q1 2026 · Mar 31, 2025 259.5M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $336.9M
Stock Repurchased Q1 2026 · Mar 31, 2025 $426.1M
Capex Q1 2026 · Mar 31, 2026 $133.4M
Capex Q1 2026 · Mar 31, 2025 $40.7M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $1.43B
Operating Cash Flow Q1 2026 · Mar 31, 2025 $818.9M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $5.49B
Cash And Equivalents Q1 2026 · Dec 31, 2025 $5.08B
Cash And Equivalents Q1 2026 · Mar 31, 2025 $4.67B
Cash And Equivalents Q1 2026 · Dec 31, 2024 $4.57B
Stockholders Equity Q1 2026 · Mar 31, 2026 $19.36B
Stockholders Equity Q1 2026 · Dec 31, 2025 $18.67B
Stockholders Equity Q1 2026 · Mar 31, 2025 $16.5B
Stockholders Equity Q1 2026 · Dec 31, 2024 $16.41B
Current Liabilities Q1 2026 · Mar 31, 2026 $3.88B
Current Liabilities Q1 2026 · Dec 31, 2025 $3.86B
Total Liabilities Q1 2026 · Mar 31, 2026 $7.12B
Total Liabilities Q1 2026 · Dec 31, 2025 $6.98B
Current Assets Q1 2026 · Mar 31, 2026 $11.73B
Current Assets Q1 2026 · Dec 31, 2025 $11.2B
Total Assets Q1 2026 · Mar 31, 2026 $26.48B
Total Assets Q1 2026 · Dec 31, 2025 $25.64B
Eps Diluted Q1 2026 · Mar 31, 2026 $4.02
Eps Diluted Q1 2026 · Mar 31, 2025 $2.49
Eps Basic Q1 2026 · Mar 31, 2026 $4.06
Eps Basic Q1 2026 · Mar 31, 2025 $2.52
Sga Expense Q1 2026 · Mar 31, 2026 $493.7M
Sga Expense Q1 2026 · Mar 31, 2025 $396.4M
Net Income Q1 2026 · Mar 31, 2026 $1.03B
Net Income Q1 2026 · Mar 31, 2025 $646.3M
Operating Income Q1 2026 · Mar 31, 2026 $1.14B
Operating Income Q1 2026 · Mar 31, 2025 $630.1M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $392.8M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $363M
Revenue Q1 2026 · Mar 31, 2026 $2.99B
Revenue Q1 2026 · Mar 31, 2025 $2.77B